Companies Investors People

Drop to look up

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

Contact
Request a Demo
Request Data Updates
Add a Company

Research

Companies
Investors
People

aVenture

Download App
Pricing
Alternatives

For iPhone and iPad

Resources

Documentation
Use Cases
CLI
MCP
Sitemap

aVenture is an AI-native agentic deep research tool for researching and finding companies and people, and is a high-quality alternative to AlphaSense, CB Insights, Crunchbase, Dealroom, Harmonic, Owler, Perplexity Finance, PitchBook, Preqin, PrivCo, Synaptic, and Tracxn.

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Terms of service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Olema Pharmaceuticals Company Profile - aVenture Research

Olema Pharmaceuticals

Olema Pharmaceuticals

Olema Pharmaceuticals is a clinical-stage biopharmaceutical company developing once-daily oral palazestrant for patients with ER+/HER2- metastatic breast cancer.

: Public company

San Francisco, CA, US🇺🇸United States

Olema Pharmaceuticals is a clinical-stage biopharmaceutical company that advances a pipeline of novel therapies for breast cancer. It applies its understanding of endocrine-driven cancers, nuclear receptors, and acquired resistance mechanisms to develop therapies for patients living with breast cancer, including OP-3136, an orally available small molecule that inhibits lysine acetyltransferase 6 (KAT6) potently and selectively; KAT6 is an epigenetic target dysregulated in breast and other cancers.

Palazestrant is a novel, orally available complete estrogen receptor antagonist (CERAN) and selective estrogen receptor degrader (SERD) that blocks both transcriptional activation function domains AF1 and AF2. It fully inhibits ER-driven transcription irrespective of ESR1 mutation status, and it is a once-daily oral medicine for breast cancer, specifically ER+/HER2- cases that have recurred or spread beyond the initial disease site.

Similar Companies

S-Biomedic

Endeavor Biomedicines

Neurona Therapeutics

Akouos

Atsena Therapeutics

BridgeBio Oncology

bbotx.com

Zentalis Pharma

zentalis.com

Semafore Pharmaceuticals

Puma Biotechnology

Veru

verupharma.com

Karyopharm Therapeutics

karyopharm.com

Oncolyze

oncolyze.com

Omeros

omeros.com

Sermonix Pharmaceuticals

sermonixpharma.com

Traws Pharma

trawspharma.com

Otricath

otricath.com

Zenopharm

Oligomerix

oligomerix.com

SELLAS Life Sciences Group

Oncotelic Therapeutics

oncotelic.com

Classification

Industry: Biopharmaceuticals
Ownership: Public
Technology: Small Molecule

Geographic Exposure

United States

Customer: Patients

Tags: Oncology

Also Known As: Olema Pharmaceuticals, Inc.
Olema Oncology

Headquarters: 780 Brannan Street
San Francisco, CA, 94103
US